Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.30 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.30 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9801323 | 0.88 | KEAP1 (0.41) | ALOX15MAPK1SMN1; SMN2SIGMAR1ACE2 | |
| SCHEMBL23254154 | 0.84 | ALOX15 (0.35) | ALOX15MAPK1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL18912885 | 0.81 | ALOX15 (0.48) | ALOX15MAPK1SIGMAR1ACE2 | |
| SCHEMBL8736521 | 0.81 | ALOX15 (0.48) | ALOX15MAPK1SIGMAR1ACE2 | |
| SCHEMBL11957693 | 0.80 | DRD2 (0.41) | — | |
| SCHEMBL9801956 | 0.80 | DRD2 (0.41) | — | |
| SCHEMBL11957694 | 0.80 | DRD2 (0.41) | — | |
| SCHEMBL15312557 | 0.78 | MAPK1 (0.53) | MAPK1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL9939558 | 0.78 | MAPK1 (0.53) | MAPK1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL9801476 | 0.78 | MAPK1 (0.53) | MAPK1ALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | GALYAN BIO INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | GALYAN BIO INC (US) | 2023-07-13 | — | — | US | disclosed |
| EP-4140481-A1 | PROTEIN-OLIGOMER BINDING AGENTS AND THERAPEUTIC USES THEREOF | Galyan Bio, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4110463-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Galyan Bio, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, HYPK, PARK7 | ALOX15 4013/4885MAPK1 3775/4885ALDH1A1 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.